TURINABOL (4-Chlorodehydromethyltestosterone 10 mg.)

As previously mentioned, Tbol is in reality a modified form of Dianabol (Methandrostenolone), whereby it is actually a combination of the chemical structures of Dianabol and Clostebol (4-chlorotestosterone). It possesses the same general chemical structure of Dianabol along with the 4-chloro substitution that Clostebol possesses. The result is that Tbol becomes a much milder hormone than its parent hormone Dianabol. The alterations to its chemical structure remove the ability for it to be able to be aromatized into Estrogen, as well as exhibiting a far weaker androgenic strength. Turinaboltherefore possesses an anabolic rating of 54, and a very low androgenic rating of 6, making its separation between anabolic and androgenic effects very distinct and favorable. Although the anabolic strength is considerably less than Dianabol’s rating of 90 – 210, the distinct distance between Turinabol’s anabolic and androgenic effects tend to be far more favorable to the individual.

Turinabol’s chemical modifications also grant it a 16 hour half-life as well as the ability to bind to SHBG (Sex Hormone Binding Globulin).

Turinabol is C17-alpha alkylated so as to allow oral bioavailability, and as a result, will exhibit a measure of liver toxicity. It also possesses a double bond between carbon 1 and carbon 2 (also known as the 1-ene carbon), and it is this double-bond that is responsible for the reduction of androgenic strength. Lastly, as previously mentioned, a chloro group has been added at the 4th carbon, responsible for rendering it unable to aromatize as well as reducing the androgenic strength even further.

Because of its distinct separation of its androgenic to anabolic effects, it is a weaker anabolic steroid than its parent hormone Dianabol. However, the assurance with Tbol is that with any apparent muscle building capability, it will present much less in the way of androgenic effects and absolutely no estrogenic effects (due to its inability to aromatize into Estrogen). Because of its fairly weaker strength than Dianabol, the doses required to elicit effects from Tbol are considered to be quite high (this will be explained shortly in the Tbol doses section of this profile).

In general, athletes and bodybuilders can expect steady and quality lean mass gains with no risk of any bloating, gyno, or any other estrogenic effects. Mass and strength gains are not known to be dramatic due to its lack of anabolic strength, but steady and quality lean gains that grow consistently over time can be expected. It is also used as an ideal cutting agent during periods of fat loss or pre-contest preparation due to its inability to convert into Estrogen. Turinabol’s capabilities really shine as an adjunct to other anabolic steroids when it is run (stacked) with other anabolic steroids due to its ability to bind to SHBG. Binding to SHBG allows more of the other anabolic steroids it is stacked with to be available to do their job, being uninhibited by SHBG, which is another advantage that it exhibits

Turinabol is a modified form of Dianabol, and while Dianabol does hold a moderate affinity for aromatization into Estrogen, Turinabol does not at all. This is the result of its 4-chloro substitution (the chloro group that has been affixed to the 4th carbon on the steroid structure), which disallows the opportunity for the aromatase enzyme to convert Turinabol into Estrogen. Turinabol is therefore not aromatized at any dose at all, and estrogenic side effects should not be considered a part of Turinabol side effects at all.

Turinabol’s chemical modification of holding a double-bond between carbons 1 and 2, as well as the 4-chloro modification, grant it with a significantly reduced androgenic strength. However, this has not eliminated Turinabol’s androgenic capabilities and although it is vastly less androgenic than most other anabolic steroids, there is still a risk with androgenic side effects (especially in those very sensitive to androgenic side effects). At lower to mid-range doses, androgenic effects should rarely be experienced due to its weakness in this department, but higher doses will elicit a greater androgenic effect, especially in females. In addition, Turinabol is indeed metabolized by the 5-alpha reductase enzyme into a stronger androgenic metabolite, but the rate of 5AR reduction that Turinabol is exposed to is known to be very minimal, and so the use of 5AR inhibitors such as Proscar, FInasteride, Dutasteride, etc. will likely not greatly reduce any androgenic activity that is resultant of Turinabol.

The potential for androgenic Turinabol side effects include: increased sebum secretion (oily skin), increased bouts of acne (linked to increased sebum secretion), bodily and facial hair growth, benign prostatic hypertrophy (BPH), and the increased risk of triggering Male Pattern Baldness (MPB) in individuals that possess the genetic trait required for the condition to manifest itself. Women will increase their chances of experiencing virilization at doses greater than 10mg per day.